These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17879084)

  • 1. Reconstruction of N-acetyltransferase 2 haplotypes using PHASE.
    Golka K; Blaszkewicz M; Samimi M; Bolt HM; Selinski S
    Arch Toxicol; 2008 Apr; 82(4):265-70. PubMed ID: 17879084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clarifying haplotype ambiguity of NAT2 in multi-national cohorts.
    Selinski S; Blaszkewicz M; Agundez JA; Martinez C; Garcia-Martin E; Hengstler JG; Golka K
    Front Biosci (Schol Ed); 2013 Jan; 5(2):672-84. PubMed ID: 23277078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling ambiguous NAT2 genotyping data.
    Agúndez JA; Golka K; Martínez C; Selinski S; Blaszkewicz M; García-Martín E
    Clin Chem; 2008 Aug; 54(8):1390-4. PubMed ID: 18664443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Algorithm for the Automated Evaluation of NAT2 Genotypes.
    Michael G; Thier R; Blaszkewicz M; Selinski S; Golka K
    Methods Mol Biol; 2018; 1655():77-96. PubMed ID: 28889379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arylamine N-acetyltransferase 2 gene polymorphism in an Algerian population.
    Chelouti H; Khelil M
    Ann Hum Biol; 2017 Sep; 44(6):531-536. PubMed ID: 28347189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in algorithms for phenotype inference: the NAT2 example.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Curr Drug Metab; 2014 Feb; 15(2):233-49. PubMed ID: 24524665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction.
    Taylor JA; Umbach DM; Stephens E; Castranio T; Paulson D; Robertson C; Mohler JL; Bell DA
    Cancer Res; 1998 Aug; 58(16):3603-10. PubMed ID: 9721868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetyltransferase 2 polymorphism and acetylation profiles in Buginese ethnics of Indonesia.
    Yuliwulandari R; Susilowati RW; Razari I; Viyati K; Umniyati H; Prayuni K
    Ann Hum Genet; 2019 Nov; 83(6):465-471. PubMed ID: 31332782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: occupational and non-occupational bladder cancer patient groups.
    Ma QW; Lin GF; Chen JG; Xiang CQ; Guo WC; Golka K; Shen JH
    Biomed Environ Sci; 2004 Sep; 17(3):291-8. PubMed ID: 15602826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N -acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer.
    Hong KU; Hein DW
    Pharmacogenet Genomics; 2023 Aug; 33(6):136-137. PubMed ID: 37306342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
    Cascorbi I; Roots I; Brockmöller J
    Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.
    Kotila OA; Fawole OI; Olopade OI; Ayede AI; Falusi AG; Babalola CP
    Pharmacogenet Genomics; 2019 Jul; 29(5):106-113. PubMed ID: 30882558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background.
    García-Closas M; Hein DW; Silverman D; Malats N; Yeager M; Jacobs K; Doll MA; Figueroa JD; Baris D; Schwenn M; Kogevinas M; Johnson A; Chatterjee N; Moore LE; Moeller T; Real FX; Chanock S; Rothman N
    Pharmacogenet Genomics; 2011 Apr; 21(4):231-6. PubMed ID: 20739907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
    Hein DW
    Oncogene; 2006 Mar; 25(11):1649-58. PubMed ID: 16550165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians.
    Gu J; Liang D; Wang Y; Lu C; Wu X
    Mutat Res; 2005 Mar; 581(1-2):97-104. PubMed ID: 15725609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inferring haplotypes at the NAT2 locus: the computational approach.
    Sabbagh A; Darlu P
    BMC Genet; 2005 Jun; 6():30. PubMed ID: 15932650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyltransferase 2 polymorphism is associated with bladder cancer risk: An updated meta-analysis based on 54 case-control studies.
    Song Y; Qi X; Liu X
    Gene; 2020 Oct; 757():144924. PubMed ID: 32622992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of computational methods in haplotype prediction.
    Xu CF; Lewis K; Cantone KL; Khan P; Donnelly C; White N; Crocker N; Boyd PR; Zaykin DV; Purvis IJ
    Hum Genet; 2002 Feb; 110(2):148-56. PubMed ID: 11935321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.